Sareum’s lead asset SDC-1801 is inching closer to completing its preclinical toxicology studies, although the decision to pursue a capsule alternative to the original suspension formulation, at the cost of a further delay in the clinical trial application (CTA) filing (now expected mid-2022), comes as a surprise. Management asserts that the new formulation adds value to the programme (removing the need to develop capsules at a later stage) and is supported by £4.6m of funds raised in calendar Q2 ....
23 Nov 2021
Sareum Holdings - SDC-1801’s clinical plan modified
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sareum Holdings - SDC-1801’s clinical plan modified
Sareum Holdings plc (SAR:LON) | 24.2 -0.6 (-9.3%) | Mkt Cap: 24.6m
- Published:
23 Nov 2021 -
Author:
Jyoti Prakash -
Pages:
5
Sareum’s lead asset SDC-1801 is inching closer to completing its preclinical toxicology studies, although the decision to pursue a capsule alternative to the original suspension formulation, at the cost of a further delay in the clinical trial application (CTA) filing (now expected mid-2022), comes as a surprise. Management asserts that the new formulation adds value to the programme (removing the need to develop capsules at a later stage) and is supported by £4.6m of funds raised in calendar Q2 ....